Methyl Jasmonate Cancer Research Results

Methyl Jasmonate — Methyl jasmonate (MeJa, MJ) is a naturally occurring, hydrophobic, volatile oxylipin and methyl ester of jasmonic acid that functions as a plant stress-response phytohormone. Pharmacologically, it is an experimental small-molecule metabolic and mitochondria-targeting anticancer agent rather than an approved anticancer drug. Its most distinctive proposed cancer-selective mechanism is disruption of the mitochondrial hexokinase-II–VDAC complex, linking inhibition of glycolytic energy metabolism to mitochondrial dysfunction and cell death. Anticancer evidence remains predominantly preclinical.

Primary mechanisms (ranked):

1. Disrupts the mitochondrial HK-II–VDAC complex, detaching hexokinase-II from mitochondria, impairing glycolytic coupling, reducing ATP production and promoting mitochondrial membrane permeabilization.
2. Induces mitochondrial dysfunction with ↓ mitochondrial membrane potential, cytochrome-c release and activation of intrinsic apoptotic signaling.
3. ↑ ROS and oxidative stress, contributing to apoptosis and pro-death autophagy; ROS can activate DDIT3/CHOP–TNFRSF10B/DR5–caspase signaling.
4. Activates intrinsic and extrinsic apoptosis, including ↑ BAX/BCL-XS, caspase-8 and caspase-3 signaling and ↓ anti-apoptotic proteins such as survivin, XIAP and CFLAR in model-dependent settings.
5. Produces cell-cycle arrest and reduced proliferation, with the affected cell-cycle phase varying among tumor models.
6. Suppresses migration, invasion and angiogenic signaling in some tumor models, including ↓ Sp1–MMP14–VEGF signaling.
7. Can sensitize cancer cells to metabolic inhibitors, cisplatin, TRAIL and ionizing radiation in preclinical combination studies.

Bioavailability / PK relevance: Human pharmacokinetic data relevant to anticancer dosing are essentially absent. MeJa is hydrophobic and poorly water-soluble, creating formulation and systemic-delivery constraints. Anticancer cell studies commonly require approximately 0.5–3 mM MeJa, although some signaling and anti-migratory effects occur at lower concentrations. Animal studies demonstrate that comparatively large systemic doses can be tolerated, but this does not establish clinically achievable or safe chronic human anticancer exposure.

In-vitro vs systemic exposure relevance: This is a major translational limitation. Many direct cytotoxicity experiments use low-millimolar MeJa concentrations, substantially higher than the micromolar concentrations typical of potent pharmacologic agents. There is insufficient human PK evidence to show that sustained low-millimolar tumor concentrations can be achieved safely. Sub-cytotoxic effects on migration, invasion and angiogenic signaling have been reported around 0.05–0.2 mM in some models. More potent synthetic MeJa derivatives are therefore an active development strategy.

Clinical evidence status: Predominantly preclinical. Evidence includes numerous cancer-cell studies and several animal tumor/metastasis models. Very limited exploratory topical human observations have been reported historically, but these do not constitute controlled anticancer trials. No established systemic anticancer indication, validated human anticancer dose, or regulatory approval exists. MeJa should therefore be classified as an experimental preclinical anticancer agent rather than an adjunct with demonstrated clinical efficacy.

Methyl Jasmonate Cancer Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr